Merck Sharp + Dohme Corp.

Modernatx, Inc.

Senomyx, Inc.

Firmenich Incorporated

Lan Zhang

Zhifeng Chen

Aimin Tang

Kalpit A Vora

Kara S Cox

Daniel DiStefano

Hua-Poo Su

Andrew J Bett

Giuseppe Ciaramella

Guy Servant

Vincent Darmohusodo

Andrew P Patron

Chad Priest

Thomas P Brady

Xiaodong Li

Hong Xu

Qing Li

Wen Zhao

Donald Karanewsky

Catherine Tachdjian

Qing Chen

Alexey Pronin

Joseph R Fotsing

Paul Brust

Dai Wang

Kapil Bahl

Victor Selchau

Arthur Fridman

Melissa Arellano

Amy Espeseth

Jing Ling

Brett Weylan Ching

Christine Shaw

Eberhard Durr

Zhiyun Wen

Mark Williams

Kenneth Simone

Craig T Przysiecki

Melissa S Wong

Pedro Cejas

Eric Yi-Chun Huang

Kerim Babaoglu

Shinu John

Danilo R Casimiro

Hanghui Liu

Ping Qiu

David C Nickle

Keping Wu

Jessica Anne Flynn

Puneet Khandelwal

Donald S Karanewsky

The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.

RSV RNA vaccines

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

Antibody neutralizing human respiratory syncytial virus

The present disclosure generally provides compounds that antagonize certain T2R taste receptors, including related uses, methods, and compositions for the reduction of bitter taste and/or the enhancement of sweet taste. In certain aspects, the disclosure provides flavored articles or flavored compositions comprising such compounds, as well as uses of such compounds to reduce the bitter taste and/or enhance the sweet taste of such flavored articles or flavored compositions.

Antagonists of T2R54 and compositions and uses thereof

The disclosure relates to stable RSV F proteins and immunogenic compositions containing the same, as well as methods of using the immunogenic compositions and compositions comprising the RSV F proteins.

Stabilized RSV F proteins and uses thereof

Herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.

Herpes simplex virus vaccine

The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.

Broad spectrum influenza virus vaccine

The present invention relates to methods for the recombinant expression ofmajor outer membrane protein (MOMP) comprising transforming a population ofhost cells with an expression vector comprising a nucleic acid molecule that encodesMOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis ofinfection and/or the effects thereof.

Recombinant expression ofMOMP antigen

HSV glycoprotein B-VSV-Gfusion proteins and variants thereof, HSV glycoprotein C antigenic peptide constructs and variants thereof, HSV immunogenic compositions and protein vaccines including the peptide constructs, and HSV DNA vaccines encoding the amino acid sequence of the peptide constructs, as well as methods of using the vaccines and compositions comprising the vaccines.

HSV antigenic peptides and HSV protein vaccines

Growing community of inventors

Chalfont, PA, United States of America

Lan Zhang